Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer

NCT00810719 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT00810719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00810719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
December 31, 2013
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer